Are Primary Care Providers Uncomfortable Providing Routine Preventive Care for Inflammatory Bowel Disease Patients?

Abstract Background Substance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort. Methods Inflammatory bowel disease participants (n = 247) were recruited via hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers as part of a larger cohort study of psychiatric comorbidity in immune-mediated inflammatory diseases. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV was administered to participants to identify lifetime SUD, anxiety disorder, and major depressive disorder. Additional questionnaires regarding participants’ sociodemographic and clinical characteristics were also completed. We examined demographic and clinical factors associated with lifetime SUD using unadjusted and adjusted logistic regression modeling. Results Forty-one (16.6%) IBD participants met the criteria for a lifetime diagnosis of an SUD. Factors associated with elevated odds of SUD were ever smoking (adjusted odds ratio [aOR], 2.96; 95% confidence interval [CI], 1.17–7.50), male sex (aOR, 2.44; 95% CI, 1.11–5.36), lifetime anxiety disorder (aOR, 2.41; 95% CI, 1.08–5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01–1.16). Conclusions One in six persons with IBD experienced an SUD, suggesting that clinicians should maintain high index of suspicion regarding possible SUD, and inquiries about substance use should be a part of care for IBD patients, particularly for men, smokers, and patients with anxiety disorders and pain.

Download Full-text

Primary Care Research: Primary care providers miss opportunities during office visits for adult preventive care

PsycEXTRA Dataset ◽

10.1037/e556272006-013 ◽

2005 ◽

Keyword(s):

Primary Care ◽

Preventive Care ◽

Primary Care Providers ◽

Care Providers ◽

Office Visits ◽

Primary Care Research ◽

Care Research

Download Full-text

Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?

Current Pharmaceutical Design ◽

10.2174/1381612825666190312113610 ◽

2019 ◽

Vol 25 (1) ◽

pp. 7-12 ◽

Cited By ~ 4

Author(s):

Marjorie Argollo ◽

Gionata Fiorino ◽

Daniela Gilardi ◽

Federica Furfaro ◽

Giulia Roda ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Health Care Providers ◽

Bowel Disease ◽

Biological Treatment ◽

Reference Product ◽

European Medicines Agency ◽

Care Providers ◽

Inflammatory Bowel ◽

To Receive ◽

The Ideal

Introduction: Biosimilars present a considerable potential to reduce costs related to clinical management allowing health-care providers to reinvest this money, leading to a wider access to an effective biological treatment with monoclonal antibodies (mAb). Infliximab biosimilars have already been incorporated in daily clinical practice and are currently used in all indications for which the reference product (RP) was approved. Areas covered: In the next few years, also adalimumab biosimilars will become available for the treatment of inflammatory bowel disease (IBD). In fact, several of them (ABP501, BI 695501, GP2017, and SB5) have been approved by the European Medicines Agency (EMA) with the same indications of the reference product (Humira ®). Initial preclinical data proved a strong similarity between all biosimilars and the RP. Moreover, phase 3 studies in rheumatoid arthritis and psoriasis showed no differences in terms of efficacy, safety, and immunogenicity. Data on IBD patients are urgently needed. Expert opinion: Biosimilars of adalimumab showed equivalent clinical efficacy to the RP in other immunemediated diseases. However, defining the ideal patient’s profile to receive or to be switched to a biosimilar, choosing one biosimilar vs. another, or cross-switching among biosimilars, will become the next challenge in IBD.

Download Full-text

The incidence and prevalence of inflammatory bowel disease in UK primary care: a retrospective cohort study of the IQVIA Medical Research Database

BMC Gastroenterology ◽

10.1186/s12876-021-01716-6 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Karoline Freeman ◽

Ronan Ryan ◽

Nicholas Parsons ◽

Sian Taylor-Phillips ◽

Brian H. Willis ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

General Practice ◽

Cohort Study ◽

Medical Research ◽

Bowel Disease ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Research Database ◽

Care Providers ◽

Inflammatory Bowel

Abstract Background Our knowledge of the incidence and prevalence of inflammatory bowel disease (IBD) is uncertain. Recent studies reported an increase in prevalence. However, they excluded a high proportion of ambiguous cases from general practice. Estimates are needed to inform health care providers who plan the provision of services for IBD patients. We aimed to estimate the IBD incidence and prevalence in UK general practice. Methods We undertook a retrospective cohort study of routine electronic health records from the IQVIA Medical Research Database covering 14 million patients. Adult patients from 2006 to 2016 were included. IBD was defined as an IBD related Read code or record of IBD specific medication. Annual incidence and 12-month period prevalence were calculated. Results The prevalence of IBD increased between 2006 and 2016 from 106.2 (95% CI 105.2–107.3) to 142.1 (95% CI 140.7–143.5) IBD cases per 10,000 patients which is a 33.8% increase. Incidence varied across the years. The incidence across the full study period was 69.5 (95% CI 68.6–70.4) per 100,000 person years. Conclusions In this large study we found higher estimates of IBD incidence and prevalence than previously reported. Estimates are highly dependent on definitions of disease and previously may have been underestimated.

Download Full-text

Evaluation of the Risk of Inflammatory Bowel Disease after the HPV Vaccination in Primary Care in Spain: A Time-Varying Cohort Analysis of Around 390,000 Girls

Drug Safety ◽

10.1007/s40264-020-01040-0 ◽

2021 ◽

Author(s):

Elisa Martín-Merino ◽

Belén Castillo-Cano ◽

Mar Martín-Pérez ◽

Ana Llorente-García ◽

Dolores Montero-Corominas

Keyword(s):

Primary Care ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Cohort Analysis ◽

Hpv Vaccination ◽

Time Varying ◽

Inflammatory Bowel

Download Full-text

The Inflammatory Bowel Disease–Focused Primary Care Provider: An Addition to the IBD Specialty Medical Home

The American Journal of Gastroenterology ◽

10.14309/ajg.0000000000001569 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Hartman Brunt ◽

J. Casey Chapman

Keyword(s):

Primary Care ◽

Inflammatory Bowel Disease ◽

Care Provider ◽

Bowel Disease ◽

Primary Care Provider ◽

Medical Home ◽

Inflammatory Bowel

Download Full-text

VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study

BMJ Open ◽

10.1136/bmjopen-2014-007306 ◽

2015 ◽

Vol 5 (3) ◽

pp. e007306-e007306 ◽

Cited By ~ 3

Author(s):

S. Hasler ◽

N. Zahnd ◽

S. Muller ◽

S. Vavricka ◽

G. Rogler ◽

...

Keyword(s):

Primary Care ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Diagnostic Delay ◽

Real Life ◽

Diagnostic Study ◽

Item Questionnaire ◽

Inflammatory Bowel

Download Full-text

Socio-anamnestic and clinical analysis of pregnant women with ulcerative colitis

Reports of Vinnytsia National Medical University ◽

10.31393/reports-vnmedical-2021-25(1)-12 ◽

2021 ◽

Vol 25 (1) ◽

pp. 65-69

Author(s):

I. V. Oleksiienko

Keyword(s):

Ulcerative Colitis ◽

Health Care ◽

Inflammatory Bowel Disease ◽

Pregnant Women ◽

Bowel Disease ◽

Clinical Analysis ◽

Chronic Inflammatory Bowel Disease ◽

Care Providers ◽

History Of ◽

Inflammatory Bowel

Annotation. At the turn of the 21st century, chronic inflammatory bowel disease (CIBD) has become a global disease with accelerating morbidity in industrialized countries with a prevalence exceeding 0.3%. These data underscore the need for research into the prevention of inflammatory bowel disease and innovations in health care systems to manage this complex and costly disease. The information from a personal anamnesis of 40 women patients with ulcerative colitis (clinical group (main). In the second group (control), 30 practically healthy pregnant women with a physiological course of gestation were included, which did not have in their history of inflammatory intestinal diseases. Statistical processing of research results was performed using the software package Statistica 6.0. The arithmetic mean (M) and the standard deviation error (± m) (p<0.05) were determined, as well as the odds ratio (OR), confidence interval (CI) at p=95%. It was found that for women with ulcerative colitis is characterized by the presence of a history of obstetric pathology, such as: spontaneous miscarriage of OR 3.33, 95% CI [1.06-10.53], p=0.04 and blood secretions of OR 3.0, 95% CI [1.00-8.98], p=0.0496; among extragenital pathology in the anamnesis: children's infectious diseases of OR 4.85, 95% CI [1.25-18.85], p=0.02, chronic bronchitis of OR 7.54, 95% CI [1,56-36, 41], p=0.01, varicose veins OR 4.33, 95% CI [1.11-16.95], p=0.035, chronic gastritis OR 6.0, 95% CI [1,23-29, 31], p=0.03, anemia of OR 15.0, 95% CI [4.53-49.68], p<0.0001, allergy history of OR 6.65, 95% CI [1.73-25.60], p=0.006; among gynecological complications – premenstrual syndrome OR 6.0, 95% CI [1.55-23.15], p=0.009, algomenorrhea OR 8.14, 95% CI [2.12-31.24], p=0.002 , salpingo-oophoritis, OR 7.54, 95% CI [1.56-36.41], p=0.01. Because CIBD during pregnancy is associated with an increased risk of adverse effects on the mother and fetus, information on socio-anamnestic and clinical analysis of pregnant women with ulcerative colitis will be useful to health care providers in making decisions about CIBD during pregnancy.

Download Full-text